Q32 Bio INC Form 4 insider transactions

Director Arthur Tzianabos reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations following a reverse stock split.

Paul Alloway, a former officer of Q32 Bio Inc., sold 268 shares of common stock on March 25, 2024, to cover withholding taxes related to the settlement of Restricted Stock Units (RSUs).

Charles Michaud Jr., an officer of Q32 Bio Inc., sold 75 shares of common stock on March 25, 2024, to cover withholding taxes related to the settlement of Restricted Stock Units (RSUs).

Arthur Tzianabos, a director of Q32 Bio Inc., acquired stock options exercisable for 12,767 shares of common stock on March 25, 2024.

Director Isaac Manke acquired stock options for 12,767 shares of Q32 Bio Inc. on March 25, 2024.

Director Mark T Iwicki acquired 25,534 stock options in Q32 Bio Inc. on March 25, 2024.

Director David S. Grayzel of Q32 Bio Inc. was granted stock options for 12,767 shares on March 25, 2024, vesting over a three-year period.

Diyong Xu, a director and 10% owner of Q32 Bio Inc., acquired stock options for 12,767 shares on March 25, 2024.

Jason Campagna, Chief Medical Officer of Q32 Bio Inc., was granted stock options to purchase 70,687 shares of common stock on March 25, 2024.

Q32 Bio Inc.'s CEO, Jodie Pope Morrison, acquired stock options for 394,445 shares on March 25, 2024.

Shelia M. Violette, Chief Scientific Officer of Q32 Bio Inc., was granted stock options to purchase 56,413 shares of common stock on March 25, 2024.

Director Kathleen Laporte acquired stock options for 12,767 shares of Q32 Bio Inc. on March 25, 2024.

Lee Kalowski, CFO and President of Q32 Bio Inc., reports the acquisition of stock options for 161,323 shares of common stock.

Director Mary Thistle acquired stock options for 12,767 shares of Q32 Bio Inc. on March 25, 2024.

Director Sven Ante Lundberg acquired stock options for 12,767 shares of Q32 Bio Inc. at an exercise price of $16.82 on March 25, 2024.

Paul Alloway, President and COO of Q32 Bio Inc., reports changes in beneficial ownership of common stock and restricted stock units following the merger with Kenobi Merger Sub, Inc.

Charles Michaud Jr., Vice President, Corporate Controller and Treasurer of Q32 Bio Inc., reports changes in beneficial ownership of common stock and restricted stock units following the merger with Kenobi Merger Sub, Inc.

Homology Medicines addresses stockholder lawsuits alleging deficiencies in the proxy statement related to the proposed merger with Q32 Bio and provides supplemental disclosures to mitigate litigation risks.